Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Simple 8-Question test may predict survival in elderly cancer patients

NCT ID NCT03449914

Knowledge-focused Sponsor: Istituto Oncologico Veneto IRCCS Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether a quick, 8-item screening tool called G8 can help predict survival and severe side effects from treatment in elderly patients (70 years and older) with metastatic colorectal cancer. The goal is to find a simple way to identify which older patients are fit enough for standard cancer treatments. The study will follow 109 patients in Italy and also test a physical performance measure called Timed Up and Go.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

109 people

The number who actually took part.

Started

Oct 2017

Expected to finish

Feb 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Elderly (\> 70 years) patients with metastatic colorectal cancer

Ages

70 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * New diagnosis of metastatic colorectal cancer, untreated in the metastatic setting * Age ≥ 70 years * Availability of clinical data * Before patient registration, written informed consent must be given according to ICH/GCP, and national/local regulations

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Elderly metastatic colorectal cancer patients are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

colorectal cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Elderly metastatic colorectal cancer patients

Contacts and locations

Locations

  • Istituto Oncologico Veneto IRCCS

    Padua, 35128, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.